Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://www.ncbi.nlm.nih.gov/pubmed/19064968 below:

BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma

Affiliations

• ¹ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

• PMID: 19064968
• PMCID: PMC3657622
• DOI: 10.1200/JCO.2008.18.5546

Item in Clipboard

Cristina R Ferrone et al. J Clin Oncol. 2009.

• ¹ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

• PMID: 19064968
• PMCID: PMC3657622
• DOI: 10.1200/JCO.2008.18.5546

Item in Clipboard

Purpose: The prognostic significance of germline BRCA1 and BRCA2 mutations in Jewish patients with pancreatic adenocarcinoma (PAC) is unknown. Our objective was to define the prevalence of BRCA1 and BRCA2 in an unselected group of Jewish patients and to compare the clinical characteristics and overall survival (OS) of patients with resected BRCA mutation-associated PAC to PAC patients without mutations.

Patients and methods: Jewish patients with PAC resected between January 1986 and January 2004 were identified. DNA was extracted from the archived material, anonymized, and genotyped for founder mutations in BRCA1 (185delAG, 5382insC) and BRCA2 (6174delT). Standard two-sided statistical tests were utilized.

Results: Of the 187 Jewish patients who underwent resection for PAC, tissue was available for 145 patients. Eight subjects (5.5%) had a BRCA founder mutation (two with BRCA1 [1.3%], six with BRCA2 [4.1%]). The BRCA2 founder mutation was identified in 4.1% of patients with pancreatic adenocarcinoma compared with only 1.1% of cancer-free Washington, DC,-area controls (4.1% v 1.1%; P = .007; odds ratio, 3.85; 95% CI, 2.1 to 10.8). Patients with and without BRCA1 or BRCA2 mutations did not differ in age (mean, 66 v 73 years; P = .6) or other clinicopathologic features. OS was not significantly different (median, 6 v 16 months; P = .35). A previous cancer was reported by 24% (35 of 145) of patients with the most common sites being breast cancer (9 of 35; 74%) and prostate cancer (8 of 35; 23%).

Conclusion: Founder mutations for BRCA1 and BRCA2 were identified in 5.5% of Ashkenazi patients operated on for PAC. BRCA2 mutations were more prevalent than documented by population studies. Consistent with previous reports, BRCA2 mutations are associated with an increased risk of PAC.

PubMed Disclaimer

Overall survival of patients stratified…

Overall survival of patients stratified by BRCA mutation.

Overall survival of patients stratified by BRCA mutation.

• Identification of germline genetic mutations in patients with pancreatic cancer.

  Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, Reidy DL, Epstein AS, Lincoln A, Saldia A, Jacobs LM, Rau-Murthy R, Zhang L, Kurtz RC, Saltz L, Offit K, Robson ME, Stadler ZK. Salo-Mullen EE, et al. Cancer. 2015 Dec 15;121(24):4382-8. doi: 10.1002/cncr.29664. Epub 2015 Oct 6. Cancer. 2015. PMID: 26440929 Free PMC article.

• High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions.

  Lucas AL, Shakya R, Lipsyc MD, Mitchel EB, Kumar S, Hwang C, Deng L, Devoe C, Chabot JA, Szabolcs M, Ludwig T, Chung WK, Frucht H. Lucas AL, et al. Clin Cancer Res. 2013 Jul 1;19(13):3396-403. doi: 10.1158/1078-0432.CCR-12-3020. Epub 2013 May 8. Clin Cancer Res. 2013. PMID: 23658460 Free PMC article.

• Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.

  Hamel N, Kotar K, Foulkes WD. Hamel N, et al. BMC Med Genet. 2003 Aug 11;4:7. doi: 10.1186/1471-2350-4-7. BMC Med Genet. 2003. PMID: 12911837 Free PMC article.

• Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.

  Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman JA, Robson ME, Offit K, Barakat RR, Soslow RA, Boyd J. Levine DA, et al. J Clin Oncol. 2003 Nov 15;21(22):4222-7. doi: 10.1200/JCO.2003.04.131. J Clin Oncol. 2003. PMID: 14615451 Review.

• Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

  Casey MJ, Bewtra C. Casey MJ, et al. Fam Cancer. 2004;3(3-4):265-81. doi: 10.1007/s10689-004-9554-y. Fam Cancer. 2004. PMID: 15516851 Review.

• Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?

  Caffo O, Veccia A, Kinspergher S, Rizzo M, Maines F. Caffo O, et al. Front Cell Dev Biol. 2018 Sep 5;6:71. doi: 10.3389/fcell.2018.00071. eCollection 2018. Front Cell Dev Biol. 2018. PMID: 30234108 Free PMC article. Review.

• Identification of germline genetic mutations in patients with pancreatic cancer.

  Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, Reidy DL, Epstein AS, Lincoln A, Saldia A, Jacobs LM, Rau-Murthy R, Zhang L, Kurtz RC, Saltz L, Offit K, Robson ME, Stadler ZK. Salo-Mullen EE, et al. Cancer. 2015 Dec 15;121(24):4382-8. doi: 10.1002/cncr.29664. Epub 2015 Oct 6. Cancer. 2015. PMID: 26440929 Free PMC article.

• Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

  Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM. Lowery MA, et al. Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8. Eur J Cancer. 2018. PMID: 29223478 Free PMC article. Clinical Trial.

• Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.

  Kim JW, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer PM, Shyr Y, Ivy SP, LoRusso PM. Kim JW, et al. Oncologist. 2021 Jul;26(7):e1104-e1109. doi: 10.1002/onco.13758. Epub 2021 May 5. Oncologist. 2021. PMID: 33742489 Free PMC article.

• BRCA mutated pancreatic cancer: A change is coming.

  Rosen MN, Goodwin RA, Vickers MM. Rosen MN, et al. World J Gastroenterol. 2021 May 7;27(17):1943-1958. doi: 10.3748/wjg.v27.i17.1943. World J Gastroenterol. 2021. PMID: 34007132 Free PMC article. Review.

1. 1. Thull DL, Vogel VG: Recognition and management of hereditary breast cancer syndromes. Oncologist 9:13-24, 2004 - PubMed
2. 1. Hartge P, Struewing JP, Wacholder S, et al: The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963-970, 1999 - PMC - PubMed
3. 1. Robson M, Dabney MK, Rosenthal G, et al: Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1:47-51, 1997 - PubMed
4. 1. Robson M, Rajan P, Rosen PP, et al: BRCA-associated breast cancer: Absence of a characteristic immunophenotype. Cancer Res 58:1839-1842, 1998 - PubMed
5. 1. Robson ME, Offit K: New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer. Lancet 350:117-118, 1997 - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3